Aggravating conditions of modern life have a great impact on human health and especially affect the upper and lower respiratory system.
By approaching innovation from a different perspective, NAUMED® is constantly seeking alternative, easily accessible, beneficial ways to combat major health problems, which torment large numbers of the population.
NAUMED® Ltd. is a medical research and development startup company, that was founded in 2015 by our medical team. Our chairman's vision is the decoding and conversion of nature's healing mechanisms into innovative medical products, targeting a series of health problems. The company's main area of focus is the upper and lower respiratory system, which our first revolutionary medical devices were developed to protect. Both Igmorino® and Anassa® delivery devices make use and take great advantage of Greek nature's valuable goods, rich in minerals, such as the Aegean sea's flower of salt, aromatic plant extracts with high healing load, as well as already known active pharmaceutical ingredients, which are used in a topical and more efficient way. An upcoming area of focus that our ongoing study will address is to validate the correlation of 21 symptoms of unknown cause (e.g. headache, dizziness, fatigue) with specific peptic disorders.
Dr. George Naoum M.D.- PhD and his team have developed Igmorino®. A low pressure upper respiratory cleansing device, that painlessly fills up the maxillary sinuses, ethmoid capsules and frontal chambers with any solution chosen.
Insight of igmorino’s efficacy using hypertonic saline solutions, based on preliminary results from observational studies obtained
Igmorino® is development ready and has been tested to over 300 people, which allowed us to improve its usability (fine tuning), gave us a good pre-market acceptance feedback and gained a solid preliminary insight of its performance/effectiveness on the conditions below:
> Treatment of acute sinusitis in 7-10 days of igmorino’s rinses (2 times/day). No antibiotics used.
> Treatment of viral infections of the upper respiratory, on 42 patients with high viral load, in 3-7 days (depending on severity of illness) of igmorino’s rinses (2 times/day).
> Unexpected efficacy on the lower respiratory in patients suffering from pneumonia - efficacy linked with sinus nitric oxide production and pulmonary surfactant.
Paranasal sinus proper fuctioning restoration & the importance of local nitric oxide (NO) production
It is known that upper airway nitric oxide (NO) is physiologically important in airway regulation and defense, and can be modulated by various airway inflammatory conditions, including allergic rhinitis and chronic rhinosinusitis – with and without polyposis. Paranasal sinuses serve as a NO producers, with concentrations typically exceeding those measured in lower airway (fractional exhaled NO or FeNO) by a few orders of magnitude. NO is an important signaling molecule involved in many physiological and pathological processes. Initially identified as a powerful vasodilator with a half-life of a few seconds, NO has since been shown to have effects on smooth muscle relaxation (including both vasodilation and bronchodilation), bacteriostasis, mucociliary function, immune response, neurologic function, and cellular surveillance for malignant transformation. The above highlight the importance of paranasal sinus health to ensure normal production and delivery of NO. Therefore, the existence of the innovative medical device Igmorino® offers medicine and humanity a weapon for the painless treatment of paranasal sinus diseases and the restoration of their normal function.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170969/
Potential uses of igmorino® as a Class III medical device
Administration exclusivity and re- patenting possibility for pharmaceutical compounds with expired patents
Given the penetration and residence time of the solution in the paranasal sinuses that Igmorino® achieves, in contrast to existing nasal irrigation devices, the possibility of topical administration of pharmaceutical compounds is offered, reducing or eliminating side effects caused by oral administration.
> Administration of corticoids
> Administration of antihistamines
> Administration of antibiotics
> Administration of intranasal vaccines
> Administration of drugs to treat neurodegenerative diseases – blood-brain barrier bypass through olfactory epithelium
Igmorino® is globally patented, including most countries of Europe, India, Mexico, Brazil, Japan, South Korea, Turkey, China, with a double patent in the USA for both the device and the methodology it operates under.
Igmorino's® nostril plugs come in two different sizes (S/M), providing perfect fit for every type of nose, for ages of 14 years onwards. They are available in four different colours, making them ideal for family use.
Igmorino's® range of solutions:
• 0,9% Sea Salt Isotonic Solution
• 2,3% Sea Salt Hypertonic Solution
• 3,5% Sea Salt Hypertonic Solution
"Five business groups were declared winners of the 7th John & Mary Pappajohn business plan contest, recently organized by the ACT (American College of Thessaloniki) entrepreneurship center. [...] Among the groups that stood out, a place also belongs to Dr. George Naoum's Igmorino. [...] It is easy to use in a simple, painless way. It is applied by the patient, relieving him dramatically, without any medical intervention.[...]"
The object and purpose of the Anassa® project is the development of an innovative device for the administration of plant extracts from aromatic and medicinal plants (AMP) of the Greek flora, which are included among the phytotherapeutic drugs of the European Medicines Agency (EMA), for the treatment of acute and chronic diseases of the lower respiratory tract, diseases affecting a large portion of the population. This proposal aims to meet the growing consumer demand for safe, environmentally friendly, efficient and innovative products, promoting the know-how, competitiveness and synergy of Greek companies.
Among the goals of Anassa® are:
(i) the promotion and protection of Greek biodiversity by promoting organic farming as a means of obtaining plant raw materials with the required specifications.
(ii) the involvement of "green technologies" in the production of innovative infusions and fortified extracts.
(iii) the establishment of an effective method of their administration in the form of a hot nebula for the treatment of serious lower respiratory problems. The normal function of the respiratory mucosa is disrupted by air pollution in modern society and predisposes to the development of respiratory dysfunction. Frequent and permanent infection of the mucosa of the bronchial tree favors the growth of microorganisms resulting in the appearance of chronic or acute infections. Inflammations cause additional burden on the loops, increased production of viscous secretions, difficulty in expectoration resulting in an increased chance of developing chronic diseases such as chronic bronchitis, bronchial asthma, COPD, etc. At the same time, we know from the traditions of the peoples that, in the treatment of respiratory diseases, the consumption of hot infusions and beverages is recommended, as they contain bioactive ingredients with antimicrobial and antioxidant properties that contribute to the healing of the respiratory mucosa.
EE1: Production of selected AMPs of superior quality.
• P1.1: Exhibition of selection of propagating material and installation of organic crops.
• P1.2: Protocols for the receipt of volatile and non-volatile components.
• P1.3: Results of extraction and distillation of AMP for two growing seasons.
• P1.4: Evaluation report of chemical composition of essential oils and infusions.
• P1.5: Standardisation of products of the selected AMP.
EE2: Preparation and chemical evaluation of herbal preparations.
• P2.1: Protocols for the receipt of essential oils, infusions and enriched extracts using green techniques.
• P2.2: Report of qualitative and quantitative composition of essential oils.
• P2.3: Chemical load evaluation report of non-volatile preparations of the content of herbal preparations in phenolic compounds.
• P2.4: Exposure of phytochemical profile of selected extracts.
• P2.5: Report with the summaries of the papers that will be sent to conferences.
EE3: Biological evaluation of herbal preparations.
• P3.1: Evaluation report of the antioxidant activity of the decoctions and enriched extracts.
• P3.2: In vivo protocols for the evaluation of prophylactic and / or therapeutic action against inflammatory conditions of the respiratory tract.
• P3.3: Report of the results of the in vivo evaluation of the 5 selected herbal preparations in terms of their anti-inflammatory action.
• P3.4: Copies of scientific publications.
EE4: Formatting of selected preparations. Development of a pharmaceutical form and an original delivery device.
• P4.1: Construction plan of the innovative Anassa® delivery device.
• P4.2: Exhibition of pilot production and shaping of the selected herbal preparation.
• P4.3: Construction of the original device Anassa® and 50 copies for clinical trials.
EE5: Clinical evaluation of the administration of the phytotherapeutic preparation with the device Anassa®.
• P5.1: Protocol of clinical study.
• P5.2: Report of the results of the comparative study on the application of the phytotherapeutic preparation and the water nebula.
• P5.3: Report of the comparative study of the use of the device Anassa® and the device of trade.
• P5.4: Report with the results of the press conference and/or the workshops.
EE6: Evaluation of the commercial potential and economic utilisation of the use of the herbal preparation with the original device Anassa®.
• P6.1 Feasibility and sustainability study.
1) In order to raise the awareness of the general public regarding the therapeutic and economic value of Greek AFF, there will be a presentation of the project at the Innovation and Entrepreneurship Center (Innovathens) that supports the transfer of views, knowledge and experience for the future of Greek entrepreneurship. The successful operation of the Hub (over 900,000 visitors a year, familiarization of 8,000 children with science and technology, over 760 events, networking events, speeches, workshops, presentations, conferences, hackathons, competitions and festivals) will help to spread the word. research results to the general public. In addition, 87 business groups have joined the Innovathens Business Accelerator, 150 people presented their ideas to future partners and investors. It is becoming clear that the expected positive results of the Anassa® project will be a driving force for the activation and cooperation of other media, but will also contribute to the support of creating a network between researchers and young entrepreneurs.
2) Presentation of research results at World and Panhellenic Pulmonary, Pathological and Pediatric Conferences and similar scientific conferences (2018-2020), organized annually by the respective scientific societies. In these events, in which the latest developments and advances of scientific studies for the treatment of respiratory diseases are presented, our participation will be of significant value, because we will present the Greek AFF as spa products of nature, which is the trend internationally.
3) Participation in a national or international conference organized by scientific companies for medicinal plants and natural products such as the Hellenic Society of Ethnopharmacology or the Society for Medicinal Plant and Natural Product Research (GA).
4) Writing a paper and publishing it in a reputable international scientific journal of pulmonological interest such as for example European Respiratory Journal, Thorax, Chest etc., but also in a reputable international scientific journal for natural products such as Planta medica, Journal of Natural Products, Phytochemistry etc.
5) Presentation of the combination of the standard delivery device and the pharmaceutical form of the herbal preparation in trade fairs with emphasis on research and innovation with conditions for participation as "success stories - innovative products".
